Financial Results for March 31, 2026
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.0 pts more than Nifty Smallcap 250 and 9.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Blue Jet Healthcare reported FY2026 revenue of Rs 10,299.85 million, up 8.7% from Rs 9,473.21 million in FY2025. Profit after tax grew 23% to Rs 3,052.03 million from Rs 2,478.16 million. EPS improved from Rs 14.29 to Rs 17.59. The Board recommended a final dividend of Rs 1.2 per share (60%) for FY2026, subject to shareholder approval. The company also proposed raising up to Rs 10,000 million through equity or convertible securities via QIP, preferential issue, or private placement. Statutory auditors issued an unmodified opinion with no qualifications. The company manufactures artificial sweeteners, contrast media intermediates, and pharma APIs as a single reportable segment.
Strong profitability growth with 23% PAT increase and 23% EPS growth. The proposed Rs 10,000 million fundraise could dilute existing shareholders but may support future expansion given significant capex underway.